All posts by Ruijie Wang

PDX Pharma invited to share success story at the 2021 OHSU “Startup Company Showcase”

5/6/2021

Dr. Wassana Yantasee, CEO, presented an invited talk at the
2021 OHSU Research Week as part of the “Startup Company Showcase”
event in which OHSU startup companies share their compelling stories on bringing
medical technologies to the clinic. PDX Pharma was one of four companies
invited to present.

PDX Pharma is grateful for the support of the BME Department
and […]

PDX Pharmaceuticals Secures Additional Investment from the Kuni Foundation to Advance New Cancer-Fighting Precision Therapies

2/9/2021

PDX Pharmaceuticals received a second round of Series A funding in the amount of $2 million from the Kuni Foundation.

See the press release here

PDX’s CEO and Founder, Wassana Yantasee, PhD commented: “My team and I are excited to embark on this next phase of our clinical development initiatives with the intention of […]

PDX Pharmaceuticals filed international patent applications (PCT) on cancer immunotherapeutics and a provisional application on COVID-19 vaccine

7/17/2020

PDX Pharmaceuticals is proud to report that we have filed two international patent applications (PCT) on cancer immunotherapeutics and a provisional application on COVID-19 vaccine today. Protection of intellectual properties (IPs) is our top priority and we work with one of the best IP law firms, Clark+Elbing, Boston, for patent application preparation and prosecution.

– […]

Augmenting the therapeutic window of radiotherapy: A perspective on molecularly targeted therapies and nanomaterials

6/30/2020

Proud to present PDX Pharma’s new review article in collaboration with OHSU and University of Texas MD Anderson Cancer Center. “Augmenting the therapeutic window of radiotherapy: A perspective on molecularly targeted therapies and nanomaterials” published in Radiotherapy and Oncology.

Highlights

Targeted therapies may augment the therapeutic window of radiotherapy, but toxicities from combining radiation and targeted […]

PDX Pharmaceuticals Names Greg Goodwin to Board of Directors

3/31/2020

PDX Pharmaceuticals named Greg Goodwin to its Board of Directors, currently consisting of Drs. Wassana Yantasee and Joe Gray.

Goodwin, a prominent business and community leader, formerly served as the Chief Executive Officer of Kuni Automotive, a Vancouver-based network of fifteen automobile dealerships in five states, including Oregon, Washington, California, Colorado, and Kansas. Goodwin retired […]

PDX Pharmaceuticals presented at Biocom’s 10th Annual Global Life Science Partnering Conference

2/28/2020

PDX Pharmaceuticals was selected to give a company presentation on the topic of “Precision medicine and therapeutic vaccines for cancer” at the Biocom’s 10th Annual Global Life Science Partnering Conference in San Diego on February 26th, 2020. We are grateful to OHSU’s Collaborations and Entrepreneurship program for its support.

PDX Pharmaceuticals raised $4M ($1.5M first milestone payment) in November of 2019 to take its new HER2-targeted therapy to clinical trials.

1/16/2020

PDX Pharmaceuticals received the Series A funding from The Wayne D. Kuni & Joan E. Kuni Foundation, based in Vancouver. This will serve as a matching fund for the phase IIB SBIR award from the NIH (max of $4M) that PDX Pharma is eligible to apply as a phase II SBIR awardee.

PDX Pharmaceuticals’ […]

siRNA therapeutics for breast cancer: recent efforts in targeting metastasis, drug resistance, and immune evasion

10/9/2019

Drs. Ngamcherdtrakul and Yantasee recently published a
review article “siRNA therapeutics for breast
cancer: recent efforts in targeting metastasis, drug resistance, and immune
evasion” in Translational Research.

In this Review, we describe recent efforts in developing siRNA therapeutics for the treatment of cancer, with particular emphasis on breast cancer. Instead of conventionally targeting proliferation and apoptosis aspects of tumorigenesis, […]

PRESIDENT SERVES ON SCIENTIFIC REVIEW PANELS FOR THE DOD AND NIH IN NOVEMBER OF 2019

10/9/2019

Dr. Wassana Yantasee, President/CEO, serves on scientific review panels for the DOD and NIH in November of 2019; the DOD’s BCRP Clinical & Experimental Therapeutics and the NIH’s SBIR/STTR on Platform Delivery Technologies for Nucleic Acid Therapeutics

PRESIDENT CHAIRED AT THE BIT’S 17TH ANNUAL CONGRESS OF INTERNATIONAL DRUG DISCOVERY SCIENCE AND TECHNOLOGY-2019 (IDDST-2019)

10/9/2019

Dr. Wassana Yantasee, President/CEO, chaired a session at the Nanotechnologies for Drug Delivery Systems section at the BIT’s 17th Annual Congress of International Drug Discovery Science and Technology-2019 (IDDST-2019) which was held in Kyoto International Conference Center on July 25-27, and gave a talk  titled “A versatile nanoparticle platform for targeted delivery of siRNA, chemodrug, […]